Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Sjogrens Syndrome - Pipeline Review, H2 2014

Published: Dec-2014 | Format: PDF | Global Markets Direct | Number of pages: 55 | Code: MRS - 18542


Global Markets Directs, Sjogren's Syndrome Pipeline Review, H2 2014, provides an overview of the Sjogren's Syndromes therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sjogren's Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sjogren's Syndrome and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Sjogren's Syndrome
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Sjogren's Syndrome and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Sjogren's Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Sjogren's Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Sjogren's Syndrome
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Sjogren's Syndrome pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content 

Table of Contents 2
List of Tables 4
List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Sjogren's Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Sjogren's Syndrome - Overview 8
Pipeline Products for Sjogren's Syndrome - Comparative Analysis 9
Sjogren's Syndrome - Therapeutics under Development by Companies 10
Sjogren's Syndrome - Therapeutics under Investigation by Universities/Institutes 11
Sjogren's Syndrome - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Sjogren's Syndrome - Products under Development by Companies 15
Sjogren's Syndrome - Products under Investigation by Universities/Institutes 16
Sjogren's Syndrome - Companies Involved in Therapeutics Development 17
Bristol-Myers Squibb Company 17
MedImmune, LLC 18
Novartis AG 19
Takeda Pharmaceutical Company Limited 20
Toleranzia AB 21
Sjogren's Syndrome - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
abatacept (recombinant) - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ABS-11 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Cell Therapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CFZ-533 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
IMSO-001 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MEDI-4920 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
MLN-3126 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
NS2 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Recombinant Protein for Sjogren's Syndrome - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Recombinant Protein to Antagonize LTB4 and C5 for Respiratory, Immunological, CNS and Hematological Disorders - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
VAY-736 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Sjogren's Syndrome - Recent Pipeline Updates 46
Sjogren's Syndrome - Dormant Projects 50
Sjogren's Syndrome - Discontinued Products 51
Sjogren's Syndrome - Product Development Milestones 52
Featured News & Press Releases 52
Dec 16, 2014: Aldeyra Therapeutics Abstract Accepted at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting 52
Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogrens syndrome 52

Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

List of Tables

Number of Products under Development for Sjogren's Syndrome, H2 2014 8
Number of Products under Development for Sjogren's Syndrome - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
umber of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Sjogren's Syndrome - Pipeline by Bristol-Myers Squibb Company, H2 2014 17
Sjogren's Syndrome - Pipeline by MedImmune, LLC, H2 2014 18
Sjogren's Syndrome - Pipeline by Novartis AG, H2 2014 19
Sjogren's Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 20
Sjogren's Syndrome - Pipeline by Toleranzia AB, H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Sjogren's Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 46
Sjogren's Syndrome - Dormant Projects, H2 2014 50
Sjogren's Syndrome - Discontinued Products, H2 2014 51

List of Figures

Number of Products under Development for Sjogren's Syndrome, H2 2014 8
Number of Products under Development for Sjogren's Syndrome - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Products, H2 2014 14
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Top 10 Targets, H2 2014 23
Number of Products by Stage and Top 10 Targets, H2 2014 23
Number of Products by Top 10 Mechanism of Actions, H2 2014 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 25
Number of Products by Top 10 Routes of Administration, H2 2014 27
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 27
Number of Products by Top 10 Molecule Types, H2 2014 29
Number of Products by Stage and Top 10 Molecule Types, H2 2014 29

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing